Rivaroxaban submitted for wider approval in EU

04/12/2012 | Fox Business

Bayer is seeking EU authorization to market anti-coagulant rivaroxaban as a pulmonary embolism therapy. Partner Johnson & Johnson will apply this quarter for FDA approval of rivaroxaban to treat venous thromboembolism, a Bayer spokeswoman said.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT